Why the study?
Does the addition of moxonidine to eprosartan reduce sympathetic hyperactivity and blood pressure in patients with hypertensive chronic renal failure?
Does the addition of moxonidine to eprosartan reduce sympathetic hyperactivity and blood pressure in patients with hypertensive chronic renal failure?
The addition of moxonidine to an angiotensin II receptor blocker normalizes sympathetic hyperactivity and further lowers blood pressure in patients with chronic renal failure.
No takes yet. Share an insight, caveat, or question.
May support moxonidine add-on in ARB-treated hypertensive renal failure; leaves open confirmation in randomized trials.
Neumann et al. (2004) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: